Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017625 | 0.79 | MAPT (0.31) | POLBLMNAALDH1A1GAAMAPT | |
| SCHEMBL10038830 | 0.77 | GAA (0.39) | POLBHPGDLMNAALDH1A1GAA | |
| SCHEMBL3589912 | 0.74 | MAPT (0.31) | HPGDMAPTSLC16A3 | |
| SCHEMBL31289246 | 0.70 | USP14 (0.38) | HPGDPKMLMNAALDH1A1GAA | |
| SCHEMBL3596446 | 0.70 | LMNA (0.31) | HPGDLMNA | |
| SCHEMBL3596451 | 0.69 | HPGD (0.31) | HPGD | |
| SCHEMBL31160192 | 0.69 | SMN1; SMN2 (0.43) | POLBALDH1A1GAAMAPT | |
| SCHEMBL7531256 | 0.66 | ALDH1A1 (0.45) | HPGDALDH1A1GAAMAPT | |
| SCHEMBL1314001 | 0.66 | AGXT (0.42) | LMNAALDH1A1MAPT | |
| SCHEMBL10766389 | 0.66 | MAOB (0.50) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| EP-2094689-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | RB1, INMT, IDH3A | POLB 3910/4885HPGD 494/4885PKM 930/4885 |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | POLB 3694/4885HPGD 375/4885PKM 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.